Exciting new cancer drug kinder than chemotherapy
Arthur, 11, was one of the first in the UK to try blinatumomab, for his type of blood cancer.
Similar Posts
Whorlton Hall: Four carers sentenced for abusing hospital patients
She said many Whorlton Hall patients were “wholly dependent on professional support”, and added: “For each of those sentenced today, it was clear from the evidence in this case that there were occasions where the care they provided was not only devoid of the appropriate respect and kindness required, but also crossed the line into…
Mental Health in the Workplace: The Overlooked Factor in Productivity
In recent years, companies have become increasingly focused on innovation, efficiency, and output. But one of the most critical factors influencing workplace productivity often goes unnoticed—mental health. While deadlines, KPIs, and performance reviews get center stage, the emotional and psychological well-being of employees is frequently sidelined. The truth is, no matter how skilled or experienced…
Nottingham attacks: NHS to investigate Valdo Calocane's case
Valdo Calocane was detained four times under the mental health act before killing three people.
Johnson & Johnson (JNJ) earnings Q4 2023
The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged. J&J also provided full-year…
Defending Eat Out to Help Out – PM's day at Covid inquiry
Arriving amongst protests, Rishi Sunak defends his time as chancellor during the pandemic, as he gives evidence to the Covid inquiry.
Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…